Estudio del mecanismo de acción de terpenos naturales contra leishmania amazonensis
Human leishmaniasis is a parasitic disease distributed in 98 countries, affecting 12 million people in the world with 2 million new cases each year. In Argentina, the endemic area of leishmaniasis corresponds to the provinces of northeast and northwest. In the endemic area of the Argentine Republic,...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Publicado: |
2019
|
| Materias: | |
| Acceso en línea: | https://bdigital.uncu.edu.ar/fichas.php?idobjeto=14234 |
| Sumario: | Human leishmaniasis is a parasitic disease distributed in 98 countries, affecting 12 million people in the world with 2 million new cases each year. In Argentina, the endemic area of leishmaniasis corresponds to the provinces of northeast and northwest. In the endemic area of the Argentine Republic, approximately 300 new cases are registered per year. L. (L.) amazonensis, one of the etiological agents of leishmaniasis in our country, is distinguished by its ability to cause a wide spectrum of clinical manifestations: from a localized cutaneous leishmaniasis, to the most serious forms (mutilating, incapacitating and frequently of little response to treatment), being one of them the mucocutaneous leishmaniasis that is frequently observed in our endemic area.The current first-line treatment, not produced in our country and with an antiquity of 70 years, is the antimonate of meglumine (Glucantime [MA]: 85 mg / mL of antimony intramuscularly, for 21 days in localized cutaneous leishmaniasis and during 28 days in mucosal leishmaniasis Treatment with MA brings with it many drawbacks: the aggressiveness that comes with its administration, the contraindication of its use during pregnancy, and a wide range of known serious side effects such as hepatic, pancreatic, renal alterations, toxicity cardiac and sudden death The current treatment, with high doses of pentavalent antimonials intramuscularly, highly painful, leads to a high degree of abandonment on the part of the patient.For years, many laboratories around the world have been devoted to the study of the biological action of new natural compounds isolated from plants. Recently it was found that compounds of the diterpene family obtained from plants affect in some way the growth of trypanosomatids (Leishmania spp and Trypanosoma cruzi) at very low concentrations and with low toxicity on mammalian cells. Therefore, we believe that it is important to look for new prophylactic alternatives based on the search for new compounds of natural origin with therapeutic potential. We propose to identify the molecular and metabolic targets for the action of these compounds and infer about the chemical groups involved in order to advance in the design of new drugs against Leishmaniasis. |
|---|
